US Pharma Company Artelo Announces Launch of Solana Reserve Asset Strategy
BlockBeats News, August 4th, Pharmaceutical company Artelo Biosciences (Nasdaq: ARTL) announced the completion of a $9.475 million off-market private placement, which will be used to launch a Solana (SOL)-centered digital asset reserve strategy, making it the first publicly traded pharmaceutical company to include SOL as a reserve asset.
This private placement includes the issuance of common stock (or pre-funded warrants) at a price of $10.45 per share, as well as two tranches of warrants with exercise prices of $10.20 and $50, respectively, with a three-year term. The transaction is expected to be completed on August 5, 2025.
Das könnte Ihnen auch gefallen
Gewinner
Neueste Krypto-Nachrichten
Tether CEO Responses to FUD: Eigenkapital der Tether Q3 Group fast 30 Milliarden US-Dollar, wobei US-Staatsanleihen einen monatlichen Nettogewinn von rund 500 Millionen US-Dollar erwirtschaften
Ethereums Nettoversorgung in den letzten 30 Tagen um 77.380 ETH
Rayls wird sein TGE am 1. Dezember haben
Ethereum-Entwickler bereiten sich auf das Fusaka-Upgrade am 3. Dezember vor.
Hasset: Wäre eine Ehre, als Notenbankchef zu dienen, wenn Trump nominiert würde
Kundenservice:@weikecs
Geschäftliche Zusammenarbeit:@weikecs
Quant-Trading & MM:[email protected]
VIP-Services:[email protected]